-
2022-501179-23-00
6
2023-03-08
atopic dermatitis
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2024-511068-10-00
5
2022-08-04
Sjögren’s Syndrome
-
2023-510054-16-00
4
2022-04-26
Primary Sjogren's syndrome
-
2024-511599-33-00
5
2021-12-22
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-503674-20-00
5
2021-12-17
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Canc
-
2024-513936-80-00
4
2021-11-12
elderly patients (> 70 years) with CLL or SLL
-
2023-506518-33-00
5
2021-11-10
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
2024-516651-41-00
5
2021-10-08
COPD : chronic obstructive Pulmonary disease
-
2023-506368-14-00
5
2021-09-07
Systemic lupus erythematosus (SLE)
-
2023-508372-10-00
4
2021-05-19
Non small Cell Lung cancer
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2024-514467-26-00
4
2021-04-07
Indolent Systemic Mastocytosis
-
2024-512028-12-00
4
2021-03-19
Advanced ROS1-positive non-small cell lung cancer
-
2024-513252-15-00
4
2021-01-28
IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
-
2024-515944-22-00
4
2021-01-19
BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
-
2023-503384-41-00
5
2020-12-22
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
-
2024-514468-26-00
9
2020-12-04
Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), O
-
2024-511033-35-00
4
2020-12-03
rheumatoid arthritis (RA)
-
2024-512269-14-00
5
2020-01-27
GIant cell Arteritis
-
2023-509908-15-00
10
2020-01-20
Mantle Cell Lymphoma
-
2024-515946-17-00
5
2019-07-22
Non Small Cell Lung Cancer
-
2024-514885-38-00
5
2019-07-11
severe forms of mucous membrane pemphigoid
-
2024-516048-24-00
4
2019-06-19
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST